Registry and cohort study of pulmonary vascular disease
Official title: National Registry and Cohort Study of Pulmonary Vascular Disease
Run by Nanjing First Hospital, Nanjing Medical University · NCT05368467 · Data updated 2026-11-12
This study looks at patients with pulmonary hypertension to understand their causes, treatments, and outcomes while building a system to collect and share this information for better future care.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Nanjing First Hospital, Nanjing Medical University Academic / other |
| Locations | 13 sites (Guangzhou, Guangdong and 12 other locations) |
| Status | Recruiting |
| Started | March 29, 2022 |
| Main results expected | December 30, 2028 |
| Study ends | December 30, 2028 |
| Registry record updated | June 26, 2025 |
| Trial ID | NCT05368467 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include newly diagnosed or previously diagnosed patients with pulmonary hypertension who have documented mean pulmonary arterial pressure greater than 20 mm Hg.
✕Probably not a fit
Patients who do not meet the hemodynamic criteria for pulmonary hypertension or lack prior documentation of these criteria will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, multicenter, prospective cohort study focuses on patients with pulmonary hypertension (PH). It aims to evaluate the causes, clinical characteristics, treatment options, and outcomes of PH patients while establishing a registration system and database for PH in China. The study will also create a web-based data acquisition system and a multicenter clinical research platform to enhance future research and health policy related to PH.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of pulmonary hypertension, ultimately enhancing patient outcomes.
How similar studies have gone: Other studies focusing on pulmonary hypertension have shown success in improving understanding and treatment, making this approach both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed or previously diagnosed patients with PH. * Documentation of mean pulmonary arterial pressure (mPAP) \>20 mm Hg by right heart catheterization, performed at any time prior to study enrollment. Exclusion Criteria: * Have not had documentation of hemodynamic criteria for PH by right heart catheterization at some time preceding study entry and following development of symptoms associated with PH. * Do not meet the required hemodynamic criteria for entry into the study.
Where it's running
-
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, China Recruiting -
Nanjing First Hospital
Nanjing, Jiangsu, China Recruiting -
General Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China Recruiting -
Beijing Anzhen Hospital of Capital Medical University
Beijing, China Recruiting -
China-japan Friendship Hospital
Beijing, China Recruiting -
Xiangya Second Hospital, Central South University
Changsha, China Recruiting
Show 7 more locations
-
West China Hospital, Sichuan University
Chendu, China Recruiting -
Nanjing Drum Tower Hospital
Nanjing, China Recruiting -
General Hospital of Northen Theater of Command
Shenyang, China Recruiting -
Tongji Hospital, Huazhong University of Science and Technology
Wuhan, China Recruiting -
Zhongnan Hospital of Wuhan University
Wuhan, China Recruiting -
First Affiliated Hospital of Xi'An Jiaotong University
Xi'an, China Recruiting -
First Hospital of Zhengzhou University
Zhengzhou, China Recruiting
Study contacts
- Study coordinator: Shao-Liang Chen, MD, PhD
- Email: chmengx@126.com
- Phone: +86-25-52271351
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding how low-load leg exercises affect muscle and blood flow in PAH patients
This substudy tests whether a gentle leg exercise program can change blood flow and oxygen use in the calf muscles of adults with pulmonary arterial hypertension.
-
Sotatercept in Japanese children with pulmonary arterial hypertension
This study tests whether sotatercept is safe and well tolerated in Japanese children with PAH when added to standard PAH treatment.
-
DIAG723 in Adults With HHT
A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.
-
See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease
Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.
-
Sotatercept in Indian adults with pulmonary arterial hypertension on standard therapy
This study tests whether adding sotatercept to current PAH medicines is safe and tolerable for adults with PAH in India.
-
Once-daily treprostinil palmitil inhalation powder for PAH
This study tests whether taking a daily inhaled treprostinil palmitil powder for 24 weeks improves exercise ability in adults with pulmonary arterial hypertension compared to a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.